Scancell Share Discussion Threads

[drdobson1] 10/8/2018 12:01

Goosey Nay even be tempted to go to AGM to voice my thanks for allowing such a great entry price.
Poor Yarquinis and baNANA.ThecALL in £6 guarantee is lOOking a BIT FOOLish if you get my drift.
PLUM will be SOOO desprit for CASH he will be donnng the VABK Robber outfit and will find himself back in the BIG HOUSE.
Hope those sewing needles for those Mail bags are sharper than is Brsin.
Does NIT matte if they put him close to home in Dartmoor as only VISitirvwil be Tarquinius SCAM member and his Many Altar EGOs will be in Cell with him.
Ha ha ha ha

[gooosed] 10/8/2018 11:58

J777J - hope you're right. Chiplin has achieved diddly imo and although I am being a bit harsh re Holloway (relatively early days for him perhaps) the US based Exec Chairman & strategy has returned no tangible benefits - apart from some cheesy Brian Epstein anecdotes !

[j777j] 10/8/2018 11:48

If she is a CRUK fundraiser,more likely she left to avoid conflict of interest in the CRUK grand challenge in which sclp is in the final 10?

[gooosed] 10/8/2018 10:35

John Glencross as has already been pointed out, was not happy and aired his discontent publicly via Twitter. Kate C-B was a Calculus representative on the Scancell BoD as we all know.

Pure speculation on my part but with zero apparent value in a US based Executive Chairman (after a US centred strategy) & the expense of a San Diego office - Kate as a member of the remuneration committee (just prior to formulating resolutions for approval at the upcoming AGM) may feel that any further enhancements are simply not justified.

Hence my feeling that the existing situation needs addressing & any further enhancements voted down. All merely imo.

Chiplin & Holloway are well passed the honeymoon period and have achieved nothing to warrant anything other than a grilling at the forthcoming AGM.

[the real lozan] 10/8/2018 10:25

Kate Cornish-Bowden -
Is an 'active' director with CALCULUS
"Kate is a non-executive Director and Chairman of the Audit Committee of Calculus VCT plc,"
And Holds a number of 'non Exec directorships' with a number of companies, including Finsbury Growth & Income Trust PLC
She ALSO resigned as a director of ARCIS Biotechnology Holdings Limited... who 'reside' at an 'interesting correspondence address' =
Calculus Capital Limited, 104 Park Street, London, United Kingdom, W1K 6NF
.
Kate is also a 'Fund-raiser' for CRUK
.
Still waters ???

[panama7] 10/8/2018 10:05

Truffle, totally agree, when you look at the share price performance of the last 6 years against all the statements emanating from various BOD members, some very serious questions need to be answered.

[truffle] 10/8/2018 09:56

Can't blame the non exec for going.
Just look at the performance of the company's share price over the past 7 years and it tells you everything.

[drdobson1] 10/8/2018 09:39

Yes Goosey and in charge of Money Committee.
Was not John Glenrose of Calcussus not being happy with 12p Raise.
Perhaps he is Not I pressed with Bonus related Percormance of BOD.
Bit like baNANA.He thinks he is on output bonus by posting Quantity NzoT quality hence 50000 pointless POsts.
Mind you hard to get OUT of NUzmBER MINDset when it was formed earning pennies fromr Nu bears of MAIL bags you sewed in the BIG house
Hi do ho

[panama7] 10/8/2018 09:34

Goosed, very good point, what is going on, still no IND completed, absolute shambles, incredibly poorly run Company by an incredibly poor BOD.

[gooosed] 10/8/2018 08:59

Calculus BoD member leaves - not stated as personal reasons . . . . hmmmmm

Questions to be asked re what value from an Exec Chairman & San Diego Office yet to secure funds.

[the real lozan] 10/8/2018 08:31

RNS - Board change -
va-Kate

[the real lozan] 09/8/2018 15:36

The 'value' of Alternative Views and BALANCE -
"But as Hardman, the City research house pointed out in a recent note, the company’s innovations are too early stage to be subjected to this sort of analysis."
Maybe why some 'City research houses' DON'T go in for =
.....
" £1 a share is 'ON THE CARDS' today" { a CLAIM made several years ago}
" This will be £6 a share in 18 months " {a CLAIM made 18 months ago}
or, When that was obviously not going to be the case in REALITY, =
" £8+ a share " { a CLAIM made several months ago now }
.....
THAT,,,Maybe WHY some 'City research houses' DON'T go in for making FALSE CLAIMS that only serve to make them look FOOLISH
OR
PROVE very COSTLY ...For anyone who acts on CLAIMS of those who DO.

[drdobson1] 09/8/2018 14:22

J777
We need posting like this NzoT the INANe ramblings of some self CONfessed Gibbering Hediot who SPROUTs Anorak Science that he Pinches from Proper SCientists.
Every time he opens his GOB the share price goes down.So wish her would shut up
A piece of Dental Floss would make a Bigger CONtribution to the share discussion here than that PLUMMET.
Bye bye baNANa your return to the Big House must be Due as your Bail CONditions demand
Ha ha ha

[j777j] 09/8/2018 13:22

Scancell Holdings part of the new cancer revolutionShare 12:48 09 Aug 2018The AIM-listed drug developer is at the vanguard of advances in the emerging field of immuno-oncologyINVESTMENTOVERVIEW: SCLPTHE BIGPICTUREThe company's innovations have shown some early promise - particularly SCIB-1, which has been used with some success to treat melanomaThe fight against cancer has moved into a new phase as drugs are developed that use the body's immune system to tackle the killer disease.And AIM-listed Scancell Holdings (LON:SCLP) is at the vanguard of advances in the emerging field of immuno-oncology and is working on two technologies that are showing early promise.In May investors got behind the business, backing a placing and open offer of new shares that brought in £8.7mln before expenses.Bankrolling development That cash will fund early clinical trials of a drug generated using its Moditope platform as well as supporting the development of its more advanced assets.They are SCIB-1 and SCIB-2, which target and stimulate existing cells that make up the body's defence mechanisms.At the turn of the year, Scancell reported the "compelling" results of a phase I/II trial of SCIB-1, and the immunotherapy has continued to impress since.Meanwhile, last December Cancer Research UK agreed to fund and sponsor a phase I/II lung cancer clinical study of its SCIB-2 vaccine in combination with another type of drug called a checkpoint inhibitor.Lung cancer is a killerLung cancer remains one of the most difficult cancers to treat and accounts for more than a quarter of all cancer deaths.That's more than breast, prostate and colon cancers combined. Around 228,000 people receive a lung cancer diagnosis in the US alone and more than 160,000 will not survive.A read-out from the study is expected in the first half of next year.ImmunoBody and Moditope Both SCIB-1 and SCIB-2 emerged from Scancell's ImmunoBody platform.MODI-1 is its first drug using the company's Moditope technology. Initially, it will be deployed in the clinic to treat breast and ovarian cancers as well as sarcoma (tumours found in fat, muscle, bone and tendons).MODI-1 acts to stimulate the production of killer CD4+ T cells that seek out and kill tumour cells that would otherwise be hidden from the immune system.  Partnership renewedScientists at the Karolinska Institute, led by Professors Lars Klareskog and Vivianne Malmström, uncovered an essential role for citrullinated proteins, which are normally associated with arthritis, in this process.On Thursday (Aug 9), the company extended its collaboration with the rheumatology of the Swedish medical research university.The share price, which has fluctuated between 10-16p in the past year, appears to have found a level recently around 12p.At that price, the company is worth just under £44mln. Whether this is a fair valuation of the business is open to interpretation.Hard to valueNormally, you would carry out discounted cash flow analysis to assess just what Scancell's assets are worth.But as Hardman, the City research house pointed out in a recent note, the company's innovations are too early stage to be subjected to this sort of analysis.Instead, it's probably worth looking at the trends within the industry and the deals being done.Last year there were 35 transactions in the oncology sector in excess of US$1bn, according to EvalutePharma,Of that total, 32 were focused on immuno-oncology. In other words, this is a particularly active (and potentially rewarding) area of R&D.As Hardman analyst Martin Hall said in his note: "Scancell's proprietary technologies are in the 'hot' area of immuno-oncology and targeting markets of significant unmet medical need."Recent deals have demonstrated the price that big pharma is willing to pay for validated assets in the field."

[drdobson1] 09/8/2018 09:26

See that Tarquinius Eat Up Poster first so well done.
I have just copied and pasted the info following baNANAs mo.
Tarquinius your post was great Until you mentioned the Hedjiot response to it.
He said I Have Foubd the answer when everyone ejse was questioning what it was about and how it msight be affected by CRUK and abiotevh.
He of course knew already and with an answer Only he knew about.
How come he knows answer to everything unless he is a EGO driven mEGOLMANIAC WELL HE HAS AN BIG EGO and is a MANUAC gufaw

[drdobson1] 09/8/2018 09:21

The company first teamed up with Sweden's world-leading medical research university two years ago
front of the karolina institute
The two are collaborating on a technology that hunts down cancer cells previously hidden from the immune system

Scancell Holdings Plc (LON:SCLP) has extended its collaboration with the rheumatology unit of the Karolinska Institute, Sweden’s world-leading medical research university.

The pair will focus on broadening the applications for Scancell’s Moditope platform, building on a relationship that’s been in place for more than two years.

The Moditope technology is central to one of the company’s main drug candidates, MODI-1, which initially will be trialled in breast and ovarian cancer as well as sarcoma (tumours found in fat, muscle, bone and tendons).

Killer T cells

The Scancell innovation acts to stimulate the production of killer CD4+ T cells that seek out and kill tumour cells that would otherwise be hidden from the immune system.

Scientists at the Karolinska Institute, led by Professors Lars Klareskog and Vivianne Malmström, uncovered an essential role for citrullinated proteins, which are normally associated with arthritis, in this process.

"We are pleased to have broadened our research collaboration with Professor Klareskog, Professor Malmström and their colleagues at the Karolinska Institute,” said Scancell’s chief scientific officer, Professor Lindy Durrant.

“Our research has shown that citrullinated proteins are involved in the control of tumour growth and we believe that this expanded collaboration will help us to develop Moditope, not only for use in cancer vaccines, but also as part of other cancer immunotherapy approaches."

[gooosed] 09/8/2018 08:40

[...] ADVFN wont allow proactive link.

[drdobson1] 08/8/2018 17:23

Evening Tosh.
Sure you are right.Hot Wings On MFFF and you and LOZ on here.
In FACt hearing on GRAVYvine that many other SCLP investors NOT only CONsider the Idiott a Proper PLUM but that his strategy of Going ALLin and Building up a big holding for the RER@TE is a BAD move.
Much better to trade and earn Freebies but of coursebaNANA is too thick for any Intilligent comment

[tosh123] 08/8/2018 17:08

It looks like Hotwings has shut the idiot up.

[gooosed] 08/8/2018 11:37

Courtesy of Twitter poster - Lindy busy as always :